Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Amicus Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from analyst coverage, with eight out of ten brokers recommending buy ratings.
• The average target price for Amicus Therapeutics shares is approximately $16.22, following various adjustments from notable institutions like UBS Group and Goldman Sachs.
• Amicus Therapeutics' stock is currently trading at $7.64, with a market capitalization of $2.35 billion and a 52-week price range between $5.51 and $12.65.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $16.2222.

A number of research analysts have recently issued reports on FOLD shares. Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Wall Street Zen lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday.

Amicus Therapeutics Price Performance

FOLD stock traded down $0.06 during trading on Thursday, hitting $7.59. 4,153,629 shares of the company's stock traded hands, compared to its average volume of 3,966,667. The business has a fifty day simple moving average of $6.53 and a 200 day simple moving average of $7.09. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of -63.24 and a beta of 0.55. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $12.65.

Institutional Trading of Amicus Therapeutics

A number of large investors have recently made changes to their positions in the company. Diversified Trust Co grew its position in shares of Amicus Therapeutics by 2.2% in the 1st quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company's stock valued at $682,000 after buying an additional 1,784 shares during the last quarter. Tempus Wealth Planning LLC increased its holdings in shares of Amicus Therapeutics by 7.2% in the first quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company's stock valued at $241,000 after purchasing an additional 1,990 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in shares of Amicus Therapeutics by 2.8% in the second quarter. CANADA LIFE ASSURANCE Co now owns 83,764 shares of the biopharmaceutical company's stock valued at $480,000 after purchasing an additional 2,263 shares during the period. Stephens Inc. AR grew its holdings in Amicus Therapeutics by 27.4% during the first quarter. Stephens Inc. AR now owns 13,655 shares of the biopharmaceutical company's stock worth $111,000 after acquiring an additional 2,938 shares during the period. Finally, Virtus Fund Advisers LLC acquired a new position in Amicus Therapeutics during the fourth quarter worth $29,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.